Stéphane de Botton, MD, PhD, on AML: The Effect of Olutasidenib on Complete Remissions

Posted: Wednesday, July 14, 2021

Stéphane de Botton, MD, PhD, of Gustave Roussy, discusses results from an interim analysis of a phase II clinical trial of olutasidenib, a small-molecule inhibitor of mutant IDH1, in patients with acute myeloid leukemia. The drug was reported to be well tolerated and induced durable complete response in a subset of patients with high-risk disease.